Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year Low – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares hit a new 52-week low on Thursday. The stock traded as low as $25.49 and last traded at $25.61, with a volume of 205,518 shares changing hands. The stock had previously closed at $26.68.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on GPCR shares. Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday, August 7th. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a report on Wednesday, September 9th. Finally, Weiss Ratings raised Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Stock Down 0.5%

The stock has a market capitalization of $1.78 billion, a PE ratio of -25.54 and a beta of -1.30. The firm’s fifty day moving average price is $42.50 and its two-hundred day moving average price is $44.87.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several large investors have recently modified their holdings of GPCR. Avoro Capital Advisors LLC lifted its holdings in Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares during the period. Wellington Management Group LLP grew its stake in shares of Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Janus Henderson Group PLC increased its position in shares of Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after purchasing an additional 264,833 shares during the last quarter. BVF Inc. IL increased its position in shares of Structure Therapeutics by 8.6% during the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Structure Therapeutics by 36.6% during the 1st quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock valued at $84,531,000 after purchasing an additional 469,554 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.